Detalhe da pesquisa
1.
Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks.
N Engl J Med;
2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38819658
2.
A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema.
J Allergy Clin Immunol Pract;
12(6): 1614-1621, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38609017
3.
Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks.
Allergy Asthma Proc;
45(1): 37-43, 2024 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37993116
4.
Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat.
Clin Transl Allergy;
13(9): e12288, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37746795
5.
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
Lancet;
401(10375): 458-469, 2023 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774155
6.
Hereditary Angioedema With Normal C1 Inhibitor: US Survey of Prevalence and Provider Practice Patterns.
J Allergy Clin Immunol Pract;
11(8): 2450-2456.e6, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720386
7.
Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation.
J Cyst Fibros;
20(5): 761-767, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33249003
8.
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
J Cyst Fibros;
20(2): 228-233, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32586736
9.
Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study.
Clin Nephrol;
84(5): 280-8, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26396097
10.
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
N Engl J Med;
369(26): 2492-503, 2013 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-24206459
11.
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
Nephrol Dial Transplant;
28(11): 2841-50, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24169612
12.
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
Am J Nephrol;
37(3): 212-22, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23467003
13.
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
Nephrol Dial Transplant;
27(5): 1942-9, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21931122
14.
Bardoxolone methyl and kidney function in CKD with type 2 diabetes.
N Engl J Med;
365(4): 327-36, 2011 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-21699484
15.
The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease.
Clin Trials;
8(2): 165-74, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21478328
16.
Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.
J Am Soc Nephrol;
22(4): 763-72, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21372210
17.
Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease.
Am J Nephrol;
33(2): 139-49, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21242674
18.
Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Nephron Clin Pract;
117(2): c151-9, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-20699620
19.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
Lancet;
376(9752): 1543-51, 2010 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-21055801
20.
Poverty and racial disparities in kidney disease: the REGARDS study.
Am J Nephrol;
32(1): 38-46, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20516678